围手术期抗生素不降低乳房再造脂肪移植术后手术部位感染
基于Epic Cosmos数据库12,247例脂肪移植手术(假体再造8,416例、自体再造3,831例)的多变量回归分析显示,围手术期抗生素并未减少术后30天手术部位感染;在假体再造队列中,围手术期抗生素反而与术后额外抗生素处方增加相关(OR 1.21,P=0.031)。糖尿病在两组中均为感染显著危险因素,假体组中较高BMI和较年轻年龄亦为危险因素。
要点
- 围手术期抗生素未降低假体或自体乳房再造脂肪移植术后SSI。
- 假体再造队列中围手术期抗生素与术后额外抗生素处方增加相关(OR 1.21)。
- 糖尿病是两组SSI的显著危险因素,应关注患者个体化风险。
核心结论
- 围手术期抗生素处方不降低假体或自体乳房再造患者脂肪移植术后SSI。
- 在假体再造患者中,围手术期抗生素与术后额外抗生素处方增加相关。
- 数据提示应重新考虑常规围手术期抗生素预防,聚焦患者个体化危险因素。
研究设计与样本
- 回顾性队列研究,查询Epic Cosmos数据库(Verona, Wisconsin)。
- 纳入2017年1月至2025年1月假体或自体乳房再造后1年内行脂肪移植的患者。
- 共分析12,247例脂肪移植手术,其中假体再造8,416例、自体再造3,831例。
- 采用多变量回归分析,纳入围手术期抗生素、年龄、BMI、糖尿病、吸烟状态、术中静脉抗生素及脂肪移植量。
主要发现
- 假体再造队列中,以术后额外抗生素处方定义感染时,围手术期抗生素(OR 1.21,P=0.031)、糖尿病(OR 1.65,P<0.0001)、较高BMI(OR 1.02,P=0.001)和较年轻年龄(OR 0.99,P=0.021)为感染显著危险因素。
- 假体再造队列中,以ICD编码定义感染时,仅BMI与SSI显著相关(OR 1.04,P=0.001)。
- 自体再造队列中,糖尿病是SSI唯一显著危险因素(OR 1.3,P=0.033)。
关键数值与推荐
- SSI定义为术后30天内出现,通过ICD编码或术后>7天开始新抗生素处方识别。
- 假体再造队列中围手术期抗生素与额外抗生素处方相关OR 1.21(P=0.031)。
- 假体再造队列中糖尿病OR 1.65(P<0.0001),BMI OR 1.02(P=0.001),年龄OR 0.99(P=0.021)。
- 自体再造队列中糖尿病OR 1.3(P=0.033)。
临床怎么用
- 乳房再造脂肪移植围手术期不应常规预防性使用抗生素以降低SSI。
- 应重点评估并优化患者个体化危险因素,如糖尿病和BMI。
- 假体再造患者中围手术期抗生素可能增加术后额外抗生素处方,需权衡利弊。
局限性
- 回顾性数据库研究,SSI识别依赖ICD编码或抗生素处方,可能存在错分。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fat grafting is commonly utilized to enhance outcomes in breast reconstruction. Despite their routine implementation, perioperative antibiotics lack sufficient evidence in reducing rates of surgical site infection (SSI). Leveraging the largest patient cohort to date, this study examines the association between perioperative antibiotics and SSI after fat grafting for breast reconstruction. METHODS: The Epic Cosmos database (Verona, Wisconsin) was queried for patients who underwent fat grafting within one year following either implant-based or autologous breast reconstruction from January 2017 to January 2025. SSIs within 30 days were identified using either International Classification of Diseases (ICD) codes or identification of a new antibiotic prescription starting >7 days post-surgery. Perioperative antibiotics, age, body mass index (BMI), diabetes, smoking status, intraoperative intravenous antibiotics, and volume of fat grafted were included for multivariable regression. RESULTS: We analyzed 12,247 fat grafting procedures (8416 implant-based, 3831 autologous). In the implant-based cohort, perioperative antibiotics (OR, 1.21; P = 0.031), diabetes (OR, 1.65; P < 0.0001), higher BMI (OR, 1.02; P = 0.001), and younger age (OR, 0.99; P = 0.021) were significant risk factors for infection, defined by additional postoperative antibiotic prescriptions. For infections defined by ICD codes, only BMI was significantly associated with SSI (OR, 1.04; P = 0.001). In the autologous cohort, diabetes was the only significant risk factor for SSI (OR, 1.3; P = 0.033). CONCLUSION: Perioperative antibiotic prescriptions do not decrease SSI after fat grafting in either implant or autologous breast reconstruction patients. However, they are associated with increased additional postoperative antibiotic prescriptions in implant-based breast reconstruction patients. These data suggest reconsidering routine perioperative antibiotic prophylaxis and focusing on patient-specific risk factors.
引用
- Shen Y, Glaeser-Khan S, Kammien AJ, et al. Perioperative Antibiotics Do Not Reduce Surgical Site Infections After Fat Grafting for Breast Reconstruction. Ann Plast Surg. 2026. PMID: 41604505. doi:10.1097/SAP.0000000000004648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。